doc.ai – Digital Health Trial


This is a research study led by the Stanford medical epilepsy team and doc.ai. Participation simply requires a few minutes per day from a smartphone. Compensation is provided and a DNA test is part of the research.

To be clear, this research does not require a change in existing medication or treatments for seizures. It is an observational trial based on information provided by participants.

Epilepsy Digital Health Trial

In September 2019, doc.ai launched a new Epilepsy Digital Health Trial to explore the use of Artificial Intelligence (A.I.) in identifying the right treatment for the right patient at the right time. The study, led by principal investigator Robert Fisher, MD PhD, professor of neurology and neurological sciences at the Stanford University School of Medicine and director of the Stanford Epilepsy Center, will deploy and test A.I. to develop a predictive model for treatment.

The at-home, HIPAA-compliant and IRB-approved Digital Health Trial seeks to enroll up to 1,000 eligible participants between September 2019 and September 2020. Participants must be between 18 and 100 years old, have an epilepsy diagnosis and a smartphone using the iOS operating system, and live in the U.S. In addition to advancing epilepsy research, participants will earn rewards, which can be redeemed in the doc.ai marketplace for products and services at the completion of the trial. Interested participants can join the Epilepsy Digital Health Trial via the doc.ai app. download the app

Once enrolled via the doc.ai app, participants will keep an online diary tracking their seizure episodes and side effects of medication for three months. Along with the self-reported data, the study will collect and analyze patients’ health data, including an array of personal-omics information, such as the genome (DNA test provided by Kailos), phenome to capture physical traits, physiome for exercise and activity tracking, pharmacome or medication tracking and finally, the exposome, which includes environmental exposures. The trial also leverages doc.ai A.I. technologies such as natural language processing for participants to capture a photograph of their medication bottles for automatic import.

“doc.ai has a robust multi-omics data pipeline, and we’re proud to contribute DNA tests free of charge to advance medicine,” said Troy Moore, Chief Scientific Officer, Kailos Genetics, Inc. “We hope to see some indications of clinical utility for DNA testing and treating someone with a variety of types of epilepsy. It’s early days, and together we’re testing a model of focused delivery to different population groups, which could strengthen links between epilepsy and genetics and show downstream outcomes.”